For instance, numerous preclinical studies are being conducted to evaluate targeting of tumor-associated factors, such as fibroblast growth factor receptor 1 protein (FGFR1), platelet-derived growth factor receptor alpha (PDGFRA), and VEGF receptor 2 (VEGFR2) [275, 276, 282]. Here, FGFR1 is linked to neoplasm.